Prostate Cancer Prevention (PDQ®): Prevention - Health Professional Information [NCI] - Overview
Note: Separate PDQ summaries on Prostate Cancer Screening, Prostate Cancer Treatment, and Levels of Evidence for Cancer Screening and Prevention Studies are also available.
Benefits From Finasteride and Dutasteride Chemoprevention
Based on solid evidence, chemoprevention with finasteride and dutasteride reduces the incidence of prostate cancer, but the evidence is inadequate to determine whether chemoprevention with finasteride or dutasteride reduces mortality from prostate cancer.
Magnitude of Effect: Absolute reduction in incidence for more than 7 years with finasteride was 6% (24.4% with placebo and 18.4% with finasteride); relative risk reduction (RRR) for incidence was 24.8% (95% confidence interval [CI], 18.6%-30.6%). There was no difference in the number of men dying from prostate cancer in the two groups, though the number of deaths was small.
In the dutasteride trial, using the restricted crude rate absolute risk reduction was 5.1% at 4 years, and RRR was 22.8% (95% CI, 15.2%-29.8%, P < .001). There was no difference in prostate cancer or overall mortality, though the number of deaths was small and none were due to prostate cancer. The reduction in prostate cancer incidence occurred primarily in Gleason 5 to 6 cancers. The reduction in incidence primarily in less aggressive cancers (i.e., Gleason 5-6) and not in more aggressive cancers (i.e., Gleason 7-10) raises the question of whether this reduction in incidence would lead to any reduction in mortality. This question is presently unanswered.
|Study Design: Two randomized controlled trials; one for finasteride and one for dutasteride.
|Internal Validity: Good for the outcome of incidence, poor for the outcome of mortality.
|External Validity: The studies focused on different populations. The finasteride trial enrolled men with a prostate-specific antigen (PSA) more than 3 ng/mL, constituting the majority of U.S. men, but men with a lower risk of cancer. In the dutasteride trial, men were at somewhat higher risk, with a PSA of 2.5 to 10.0 and a prior negative biopsy. As such, results are generalizable primarily to these respective populations.